DAFTAR PUSTAKA
ACS. (2011). Breast Cancer What is cancer ? (pp. 1–134).
Ambudkar, S. V, Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003). P-glycoprotein: from genomics to mechanism. Oncogene, 22(47), 7468–85. doi:10.1038/sj.onc.1206948
Amerongen, R. Van, & Berns, A. (2006). TXR1-mediated thrombospondin repression : a novel mechanism of resistance to taxanes ? Genes & Development, 20, 1975–1981. doi:10.1101/gad.1460806
Ameyaw M M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. (2001). ABCB1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 11, 217-221
Albrektsen, G., Heuch, I. & Thoresen, S.Ø., (2010). Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway. BMC cancer, 10, 226.
Ashariati, A., (2008). Polymorphism C3435T of The MDR-1 Gene Predict Response to Preoperative Chemotherapy in Locally Advanced Breast Cancer with Her2 / neu Expression. Acta Med Indones-Indones J Inter Med, 40(4), 187–191.
Balram, C. et al., (2003). Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population : phenotypic – genotypic correlates. Br J Clin Pharmacol, 56, 78–83.
Bartoszek, A. (2002). Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase ; overview of its biological and. Acta Biochimica Polonica, 49(2), 323–331.
Biemans-Oldehinkel, E., Doeven, M. K., & Poolman, B. (2006). ABC transporter architecture and regulatory roles of accessory domains. FEBS Letters, 580(4), 1023–35
Bressolle, F., Jacquet, J., Galtier, M., Jourdan, J., & Donadio, D. (1992). Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol, 30, 215–218.
Calado, R. T., Falcao, R. P., Garcia, A. B., & Gabellini, S. M. (2002). Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34 hematopoietic stem cells. Haematologica, 87(6), 564–568.
Callies, S., de Alwis, D. P., Wright, J. G., Sandler, A., Burgess, M., & Aarons, L. (2003). A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemotherapy and Pharmacology, 51(2), 107–18. doi:10.1007/s00280-002-0542-3
Cascorbi, I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacology & Therapeutics, 112, 457–473. doi:10.1016/j.pharmthera.2006.04.009
Chang, H., Rha, S. Y., Jeung, H., Im, C., Ahn, J. B., Kwon, W. S., … Chung, H. C. (2008). Association of the ABCB1 gene polymorphisms 2677G > T / A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of Oncology, 2677, 1–6. doi:10.1093/annonc/mdn624
Chargari, C., Kirov, K. M., Bollet, M. a, Magné, N., Védrine, L., Cremades, S., … Kirova, Y. M. (2011). Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treatment Reviews, 37(4), 321–30. doi:10.1016/j.ctrv.2010.08.007
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy. Cardiology, 115(2), 155–62. doi:10.1159/000265166
Cizmarikova, M., Wagnerova, M., Schonova, L., Habalova, V., Kohut, A., Linkova, A., … Mirossay, L. (2009). MDR1 ( C3435T ) polymorphism : relation to the risk of breast cancer and therapeutic outcome. The Pharmacogenomics Journal, 10(1), 62–69. doi:10.1038/tpj.2009.41
Crawford, J., Dale, D. C., Lyman, G. H., & Crawford, C. N. (2004). Chemotherapy-Induced Neutropenia, 228–237. doi:10.1002/cncr.11882
CTCAE, C. T. C. for A. E. (2010). Common Terminology Criteria for Adverse Events ( CTCAE ). Publish (Vol. 2009, pp. 0–71). National Cancer Institute, Cancer Therapy Evaluation Program.
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Tacca, M. Del. (2002). Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs. Clin Pharmacokinet, 41(6), 431–444.
Erdélyi, D.J. et al., (2006). The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cellular immunology, 244(2), 121–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17434155 [Accessed November 26, 2014].
Evans, T. R. J., Yellowlees, A., Foster, E., Earl, H., Cameron, D. a, Hutcheon, A. W., … Mansi, J. L. (2005). Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 23(13), 2988–95. doi:10.1200/JCO.2005.06.156
Fajac, A., Gligorov, J., Rezai, K., Levy, P., Levy, E., Selle, F., … Lokiec, F. (2010). Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients, 560–566. doi:10.1038/sj.bjc.6605789
Franke, R. M., Gardner, E. R., & Sparreboom, A. (2010). Pharmacogenetics of Drug Transporters. Current Pharmaceutical Design, 16, 220–230.
Fung, K. L., & Gottesman, M. M. (2009). A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochimica et Biophysica Acta, 1794(5), 860–71. doi:10.1016/j.bbapap.2009.02.014
Garattini, S. (2006). Pharmacokinetics in cancer chemotherapy, 3. doi:10.1016/j.ejca.2006.10.015
Gasparini, G., Longo, R., Torino, F., Gattuso, D., Morabito, A., & Toffoli, G. (2006). Is tailored therapy feasible in oncology ? Critical Reviews in Oncology/Hematology, 57, 79–101. doi:10.1016/j.critrevonc.2005.07.003
Gewirtz, D. A. (1999). A Critical Evaluation of the Mechanisms of Action Proposed for the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin. Biochemical Pharmacology, 57(98), 727– 741.
Gillet, J., Efferth, T., & Remacle, J. (2007). Chemotherapy-induced resistance by ATP-binding cassette transporter genes, 1775, 237–262. doi:10.1016/j.bbcan.2007.05.002
Goldhirsch, A., Glick, J. H., Gelber, R. D., & Coates, A. S. (2001). Meeting Highlights : International Consensus Panel on the Treatment of Primary Breast Cancer. Journal of Clinical Oncology, 19(18), 3817–3827.
Goto, S., Ihara, Y., Urata, Y., Izumi, S., Abe, K., Koji, T., & Kondo, T. (2001). Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 15(14), 2702– 14. doi:10.1096/fj.01-0376com
Gottesman, M. M. (2002). Mechanisms of Cancer Drug Resistance.
Annu.Rev.Med, 53, 615–27. Retrieved from
http://www.medicine.wisc.edu/~williams/drugresistance.pdf
Gustafson, D. L., & Page, R. L. (2013). Cancer Chemotherapy. Withrow and MacEwen’s Small Animal Clinical Oncology, 5/e (Fifth Edit., pp. 157–179). Elsevier Inc. doi:10.1016/B978-1-4377-2362-5.00011-6
Gwak, G., Kim, J.-Y., Park, K., Shin, Y. J., Cho, H., Park, S. J., … Han, S. (2011). Comparison of Doxorubicin plus docetaxel neoadjuvant chemotherapy with Doxorubicin plus vinorelbine in primary breast cancer. J Breast Cancer, 14(2), 129–34. doi:10.4048/jbc.2011.14.2.129
Huang, Y. (2007). Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Reviews, 26(1), 183–201. doi:10.1007/s10555-007-9050-6
Henderson, I.C. et al., (2003). Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. Journal of Clinical Oncology, 21(6), pp.976–983.
Ih, A. (2013). A Review on Aetio-Pathogenesis of Breast Cancer. J Genet Syndr Gene Ther, 4(5), 1–4. doi:10.4172/2157-7412.1000142
Joerger, M., Huitema, a D. R., Meenhorst, P. L., Schellens, J. H. M., & Beijnen, J. H. (2005). Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemotherapy and Pharmacology, 55(5), 488–96. doi:10.1007/s00280-004-0900-4
Katzung, B. (2003). Chapter 55: Cancer chemotherapy. In Basic & Clinical Pharmacology (pp. 1281–1290).
Kroetz, D.L. et al., (2003). Sequence diversity and haplotype structure in the human ABCB1 ( MDR1 , multidrug resistance transporter ) gene. Pharmacogenetics, 13, pp.481–494.
Kudzi, W., Dodoo, A.N.O. & Mills, J.J., (2010). Genetic polymorphisms in MDR1 , CYP3A4 and CYP3A5 genes in a Ghanaian population : a plausible explanation for altered metabolism of ivermectin in humans ? BMC Medical Genetics, 11, p.111.
Lam, P. et al., (2000). The Association of Increased Weight , Body Mass Index , and Tissue Density with the Risk of Breast Carcinoma in Vermont. CANCER, 89(2), pp.370–74.
Lalami, Y., Paesmans, M., Muanza, F., Barette, M., Plehiers, B., Dubreucq, L., … Klastersky, J. (2006). Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients , focusing on regimen-specific risk factors ? A retrospective analysis. Annals of Oncology, 17(December 2005), 507–514. doi:10.1093/annonc/mdj092
Lazo, J. S., & Schwartzt, P. E. (1985). Rapid Distribution of Adriamycin in the Ascitic and Pleural Fluid of Women with Ovarian Carcinomas. Gynecologic Oncology, 21, 65–72.
Lei, H., Wang, X., & Wu, C. (2012). Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations. Journal of Molecular Graphics & Modelling, 38, 279–89. doi:10.1016/j.jmgm.2012.05.006
Mary Ameyaw, M., & McLeod, H. L. (2006). Improving The Efficacy And Safety Of Anticancer Agents-The Role Of Pharmacogenetics. Novel Anticancer Agents.
McCarthy, A.R., (2006). Biological Activity of Steroid Analogues: Synthesis and Receptor/Enzyme Interactions. University of Canterbury
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines : Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev, 56(2), 185–229. doi:10.1124/pr.56.2.6.185
Monneret, C. (2001). Recent developments in the field of antitumour anthracyclines. Eur.J.Med.Chem, 36, 483–493.
Morris, C. et al., 2009. Trends in Cancer Incidence , Mortality , Risk Factors , Health Behaviors in California. In Cancer Surveillance section. pp. 17–19.
Ostad, S. N., & Parsa, M. (2011). Breast Cancer from Molecular Point of View : Pathogenesis and Biomarkers. In M. Gunduz & E. Gunduz (Eds.), Breast Cancer-Focusing Tumor Microenvironment, Stem Cells and Metastasis (1st ed., pp. 103–121). Tehran: InTech.
Oswald, S., Grube, M., Siegmund, W., & Kroemer, H. K. (2007). Transporter-mediated uptake into cellular compartments. Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 37(10-11), 1171–95. doi:10.1080/00498250701570251
Panaretakis, T., Laane, E., Pokrovskaja, K., Bjo, A., Moustakas, A., Zhivotovsky, B., … Grande, D. (2005). Doxorubicin Requires the Sequential Activation of Caspase-2 , Protein Kinase C , and c-Jun NH 2 -terminal Kinase to Induce Apoptosis , 16(August), 3821–3831. doi:10.1091/mbc.E04
Patel, K. J., & Tannock, I. F. (2009). The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer, 9, 356. doi:10.1186/1471-2407-9-356
Peterson, C., & Trouet, A. (1978). Transport and Storage of Daunorubicin and Doxorubicin in Cultured Fibroblasts. Cancer Research, 38, 4645–4649.
Plana, J. C. (2011). Chemotherapy and the Heart. Revista Española de Cardiología (English Edition), 64(5), 409–415. doi:10.1016/j.rec.2010.12.019
Preobrazhenskaya, M. N., Tevyashova, A. N., & Olsufyeva, E. N. (2006). Second Generation Drugs-derivatives of Natural Antitumor Anthracycline Antibiotics Daunorubicin , Doxorubicin and Carminomycin. J Med Sci, 26(4), 119–128.
Puma, N., Ruggiero, A., Ridola, V., Ilaria, M., Giorgio, L., Stefano, A., … Rosa, G. D. E. (2008). Anthracycline-related cardiotoxicity : risk factors and therapeutic options in childhood cancers. SIGNAE VITAE, 3(1), 30–34.
Raisch, D. W., Holdsworth, M. T., Winter, S. S., Hutter, J. J., & Graham, M. L. (2003). Economic Comparison of Home-Care-Based versus Hospital- Based Treatment of Chemotherapy-Induced Febrile Neutropenia in Children. Value in Health, 6(2), 158–166. doi:10.1046/j.1524-4733.2003.00219.x
Robert, J., Morvan, L., Smith, D., Pourquier, P., & Bonnet, J. (2005). Predicting drug response and toxicity based on gene polymorphisms, 54, 171–196. doi:10.1016/j.critrevonc.2005.01.005
Rowinsky, E. K. (1997). The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu.Rev.Med, 48, 353–74. doi:10.1146/annurev.med.48.1.353
Rowinsky, E. K. (1997). The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu.Rev.Med, 48, 353–74. doi:10.1146/annurev.med.48.1.353
Rudek, M. a, Sparreboom, A., Garrett-Mayer, E. S., Armstrong, D. K., Wolff, a C., Verweij, J., & Baker, S. D. (2004). Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. European Journal of Cancer, 40(8), 1170–8. doi:10.1016/j.ejca.2003.12.026
Schimmel, K., Straaten, T. Van Der, & Bogaartz, J. (n.d.). Doxorubicin And Cpec Induced Cardioxicity : association with the GTPase gene Rac2 , and drug transporter genes MRP1 and MRP2.
Schwartz, J. et al., (2005). Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Annals of oncology, 16(2), pp.247–52.
Sharom, F. J. (2008). ABC multidrug transporters : structure , function and role in chemoresistance. Pharmacogenomics, 9, 105–127.
Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. P. (2011). Mechanisms and management of doxorubicin cardiotoxicity. Herz, 36(4), 296–305. doi:10.1007/s00059-011-3470-3
Simůnek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., & Gersl, V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports,
61(1), 154–71. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/19307704
Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D., Sparreboom, A., & Mielke, S. (2006). Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. European Journal Of Cancer, 42, 2893–2896. doi:10.1016/j.ejca.2006.06.017
Smith, K. (2002). Genetic Polymorphism And Snps (Pp. 1–13). Retrieved From http://grants.nih.gov
Society, A. C. (2011). Breast Cancer.
Sparreboom, A., Danesi, R., Ando, Y., Chan, J., & Figg, W. D. (2003). Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates, 6, 71–84. doi:10.1016/S1368-7646(03)00005-0
Sugunan, S. L. C. (2008). Pharmacogenetics Of Doxorubicin In Asian Breast Cancer Patients. National university of Singapore.
Taheri, M., Mahjoubi, F., & Omranipour, R. (2010). Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet.Mol.Res, 9(1), 34–40.
Tran, A. Et Al., (2006). Pharmacogenetics And Genomics Pharmacokinetics And Toxicity Of Docetaxel : Role Of CYP3A, MDR1, And GST Polymorphisms. Clinical Pharmacology & Therapeutc, 79(6), Pp.570–581.
Tan, S., Lee, S., & Goh, B. (2008). Pharmacogenetics in Breast Cancer Therapy Pharmacogenetics in Breast Cancer Therapy. Clinical Cancer Res, 14, 8027– 8041. doi:10.1158/1078-0432.CCR-08-0993
Tandon, V. R., Kapoor, B., Bano, G., Gupta, S., Gillani, Z., & Kour, D. (2006). P-glycoprotein : Pharmacological relevance relevance. Indian J Pharmacol, 38(1), 13–24.
Thorn, C., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T., & Altman, R. (2011). Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics, 21(7), 440–446. doi:10.1097/FPC.0b013e32833ffb56.Doxorubicin
Tsai, C., Sauna, Z. E., Kimchi-sarfaty, C., Ambudkar, S. V, Gottesman, M. M., Nussinov, R., & Aviv, T. (2008). Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. J.Mol.Biol, 383, 281–291. doi:10.1016/j.jmb.2008.08.012
Turgut, S., Yaren, A., & Kursunluoglu, R. (2007). MDR1 C3435T Polymorphism in Patients with Breast Cancer. Archives of Medical Research, 38, 539–544. doi:10.1016/j.arcmed.2007.02.005
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2009). Human ATP-binding cassette ( ABC ) transporter family. Human Genomics, 3(3), 281–290.
cardiotoxicity. Archives of Toxicology, 85(5), 525–35. doi:10.1007/s00204-010-0615-8
Vulsteke, C., Lambrechts, D., Dieudonné, A., Hatse, S., Brouwers, B., Brussel, T. Van, … Wildiers, H. (2013). Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Annals of Oncology, 1–13. doi:10.1093/annonc/mdt008
Warren, B.S. & Devine, C., (2003). Breast Cancer in Women from Different Racial / Ethnic Groups. , (April), pp.1–5.
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Abcb, O. (2005). Multidrug resistance polypeptide 1 ( MDR1 , ABCB1 ) variant 3435C > T affects mRNA stability. Pharmacogenetics and Genomics, 15, 693–704.
Westbrook, K., & Stearns, V. (2013). Pharmacology & Therapeutics Pharmacogenomics of breast cancer therapy : An updatePharmacology and Therapeutics, 1–11. doi:10.1016/j.pharmthera.2013.03.001
Wiechec, E., & Hansen, L. L. (2009). The effect of genetic variability on drug response in conventional breast cancer treatment. European Journal of Pharmacology, 625(1-3), 122–130. doi:10.1016/j.ejphar.2009.08.045
Yan-hong, L. I., Yong-hua, W., Yan, L. I., & Ling, Y. (2006). MDR1 Gene Polymorphisms and Clinical Relevance. Acta Genetica Sinica, 33, 93–104.
Yusuf, S. W., Ilias-Khan, N. a, & Durand, J.-B. (2011). Chemotherapy-induced cardiomyopathy. Expert Review of Cardiovascular Therapy, 9(2), 231–43. Retrievedfromhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=33 22442&tool=pmcentrez&rendertype=abstract
